ArticlePlant biotechnology (Tokyo, Japan)2025
Toward the commercialization of recombinant pharmaceuticals expressed in plants.
Article in Plant biotechnology (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gene Editing of Nicotiana benthamiana Architecture for Space-Efficient Production of Recombinant Proteins in Closed Environments.Plant biotechnology journal · 2026Article
- The Nicotiana benthamiana Biofactory.Plant biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent developments have shown that the production of recombinant proteins in plants is more useful than in microbial, insect, or mammalian cell-based expression systems in terms of cost-effectiveness, scalability, safety, and sustainability. Furthermore, transient expression systems in plants may be superior to stable transgenic plants in terms of cost, yield, environmental impact, and regulation compliance. Recombinant proteins, such as enzymes, growth factors, scaffolds, and antibodies are in high demand for use in the food and chemical industries, and will be in even greater demand for diagnostic, therapeutic, and pharmaceutical applications that require high-quality proteins. In this review, we summarize the comparison of recombinant protein expression strategies in mammalian cells, microorganisms, insects, and plants. Furthermore, the efficacy of protein expression in plant cultivation environments, the optimal protein extraction, purification methods, and costs and risks are discussed. We should be aware that the production of recombinant proteins has not only scientific challenges, but also economic and political issues that must be overcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.